drugset / Trial / NCT05717400
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
NaSingle-groupOpen-labelTreatment
Summary
To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
Timeline
- Start
- 2023-03-17
- Primary completion
- 2024-08-29
- Completion
- 2024-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Ribavirin | Small molecule | — | Oral |
| Subject | Sofosbuvir | Small molecule | — | Oral |
| Subject | Voxilaprevir | Small molecule | — | Oral |
| Subject | velpatasvir | Other / unclassified | — | Oral |